Holen Sie sich die Stockscreener-App
4.12
2.60%
-0.11
Vorhandelsmarkt:
4.15
0.03
+0.73%
Schlusskurs vom Vortag:
$4.23
Offen:
$4.26
24-Stunden-Volumen:
892.37K
Relative Volume:
0.51
Marktkapitalisierung:
$516.85M
Einnahmen:
$44.55M
Nettoeinkommen (Verlust:
$-83.78M
KGV:
-5.2997
EPS:
-0.7774
Netto-Cashflow:
$-52.99M
1W Leistung:
-1.20%
1M Leistung:
-0.72%
6M Leistung:
-27.97%
1J Leistung:
+79.91%
1-Tages-Spanne:
$4.115
$4.29
1-Wochen-Bereich:
$3.98
$4.29
52-Wochen-Spanne:
$2.222
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Firmenname
Aquestive Therapeutics Inc
Sektor
Telefon
908-941-1900
Adresse
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.12 | 530.65M | 44.55M | -83.78M | -52.99M | -0.7774 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-10 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | Raymond James | Outperform |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-04-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-03 | Eingeleitet | Lake Street | Buy |
| 2018-08-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-08-20 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten
AQST Stock Chart | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
Aquestive Therapeutics Charts Cautious, Liquid Path Forward - TipRanks
Aquestive Therapeutics Q1 earnings call highlights - MSN
Aquestive Therapeutics CEO sells $35,413 in company stock By Investing.com - Investing.com South Africa
Aquestive Therapeutics CEO sells $35,413 in company stock - Investing.com UK
PRN_FinancialWrapper - FinancialContent
Aquestive secures $150 million debt facility with Oaktree By Investing.com - Investing.com Nigeria
Aquestive targets Q3 FDA resubmission for Anaphylm and projects >$150M cash at launch - MSN
A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $6 to $9 - Moomoo
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Ardent Health Partners, Inc. (ARDT) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
All News about Aquestive Therapeutics, Inc.Common Stock - The Chronicle-Journal
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Aquestive Says It’s on Track to Launch Anaphylm Studies for FDA - Allergic Living
Analysts Have Made A Financial Statement On Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) First-Quarter Report - Moomoo
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2026 Earnings Call Transcript - Insider Monkey
Citizens reiterates Aquestive stock rating on Anaphylm progress By Investing.com - Investing.com South Africa
Citizens reiterates Aquestive stock rating on Anaphylm progress - Investing.com
Aquestive Therapeutics Signals Momentum In Earnings Call - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript Summary - Moomoo
Aquestive Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AQST) 2026-05-14 - Seeking Alpha
Aquestive Therapeutics Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Aquestive’s Q1 2026 earnings beat forecasts, stock surges - Investing.com Nigeria
Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript - Benzinga
Aquestive Therapeutics (AQST) reports Q1 loss, beats revenue estimates - MSN
Compared to estimates, Aquestive Therapeutics (AQST) Q1 earnings: A look at key metrics - MSN
AQST Achieves Strong Q1 Revenue and FDA Progress - GuruFocus
Aquestive Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com Canada
AQST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Aquestive Therapeutics Incenters five-year term loan facility of up to $150 million on May 12, 2026SEC filing - marketscreener.com
Aquestive Secures New Oaktree Term Loan to Fund Anaphylm - TipRanks
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's After-Market SessionAquestive Therapeutics (NASDAQ:AQST) - Benzinga
Aquestive Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Aquestive Therapeutics: Q1 Earnings Snapshot - KTVB
Aquestive Therapeutics (AQST) trims Q1 loss and secures $150M Oaktree debt facility - Stock Titan
BRIEF-Aquestive Therapeutics, Inc. Q1 Revenue USD 14.446 Million Vs. IBES Estimate USD 10.9 Million - TradingView
Aquestive Therapeutics, Inc. Reaffirm Earnings Guidance for the Full Year 2026 - marketscreener.com
Aquestive Therapeutics Signs New $150 Million Debt Facility - Moomoo
Aquestive Therapeutics Secures $150M Refinancing Deal Ahead of Potential Anaphylm Launch - citybiz
Aquestive Therapeutics sees $150M debt refinancing - ROI-NJ
Aquestive secures $150 million debt facility with Oaktree - Investing.com UK
Aquestive Therapeutics Announces $150 Million Debt Refinancing to Support Anaphylm™ Launch if Approved by FDA - Quiver Quantitative
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree - The Manila Times
Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.92%
4.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):